Wellington Shields & Co. LLC increased its position in Johnson & Johnson (NYSE:JNJ) by 1.0% during the third quarter, HoldingsChannel reports. The firm owned 43,047 shares of the company’s stock after buying an additional 415 shares during the quarter. Johnson & Johnson accounts for approximately 1.8% of Wellington Shields & Co. LLC’s holdings, making the stock its 6th biggest position. Wellington Shields & Co. LLC’s holdings in Johnson & Johnson were worth $5,597,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Landmark Financial Advisors LLC lifted its holdings in shares of Johnson & Johnson by 0.4% in the 2nd quarter. Landmark Financial Advisors LLC now owns 1,962 shares of the company’s stock worth $259,000 after purchasing an additional 7 shares in the last quarter. Paradigm Financial Advisors LLC lifted its holdings in shares of Johnson & Johnson by 0.3% in the 2nd quarter. Paradigm Financial Advisors LLC now owns 2,649 shares of the company’s stock worth $350,000 after purchasing an additional 9 shares in the last quarter. Premier Asset Management LLC lifted its holdings in shares of Johnson & Johnson by 0.4% in the 2nd quarter. Premier Asset Management LLC now owns 2,749 shares of the company’s stock worth $363,000 after purchasing an additional 12 shares in the last quarter. Lbmc Investment Advisors LLC lifted its holdings in shares of Johnson & Johnson by 0.4% in the 2nd quarter. Lbmc Investment Advisors LLC now owns 3,718 shares of the company’s stock worth $492,000 after purchasing an additional 14 shares in the last quarter. Finally, Halbert Hargrove Russell LLC lifted its holdings in shares of Johnson & Johnson by 0.4% in the 2nd quarter. Halbert Hargrove Russell LLC now owns 3,523 shares of the company’s stock worth $466,000 after purchasing an additional 15 shares in the last quarter. Institutional investors own 65.70% of the company’s stock.

A number of equities analysts recently issued reports on JNJ shares. Leerink Swann reiterated an “outperform” rating and issued a $165.00 target price (up from $150.00) on shares of Johnson & Johnson in a report on Wednesday, October 18th. Royal Bank of Canada increased their price target on Johnson & Johnson from $144.00 to $147.00 and gave the company an “outperform” rating in a research report on Wednesday, October 18th. Stifel Nicolaus increased their price target on Johnson & Johnson from $140.00 to $142.00 and gave the company a “hold” rating in a research report on Wednesday, October 18th. BMO Capital Markets reissued a “positive” rating and issued a $152.00 price target (up from $145.00) on shares of Johnson & Johnson in a research report on Wednesday, October 18th. Finally, Wells Fargo & Co reissued an “outperform” rating and issued a $155.00 price target (up from $149.00) on shares of Johnson & Johnson in a research report on Wednesday, October 18th. Four research analysts have rated the stock with a sell rating, eight have assigned a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $146.16.

Shares of Johnson & Johnson (JNJ) opened at $129.53 on Friday. Johnson & Johnson has a 12-month low of $114.23 and a 12-month high of $148.32. The stock has a market capitalization of $347,984.94, a price-to-earnings ratio of 17.74, a PEG ratio of 2.33 and a beta of 0.74. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, January 23rd. The company reported $1.74 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.02. Johnson & Johnson had a return on equity of 27.80% and a net margin of 1.70%. The firm had revenue of $20.20 billion during the quarter, compared to analyst estimates of $20.08 billion. During the same period last year, the firm posted $1.58 EPS. The business’s revenue was up 11.5% compared to the same quarter last year. sell-side analysts predict that Johnson & Johnson will post 8.08 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th will be given a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 2.59%. The ex-dividend date is Monday, February 26th. Johnson & Johnson’s dividend payout ratio is presently 861.54%.

COPYRIGHT VIOLATION NOTICE: “Wellington Shields & Co. LLC Has $5.60 Million Position in Johnson & Johnson (JNJ)” was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this story on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this story can be viewed at https://www.dailypolitical.com/2018/02/11/wellington-shields-co-llc-has-5-60-million-position-in-johnson-johnson-jnj.html.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.